Ascendis Pharma A/S Forecasted to Earn Q3 2024 Earnings of $0.85 Per Share (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Leerink Partnrs boosted their Q3 2024 earnings estimates for Ascendis Pharma A/S in a note issued to investors on Wednesday, September 4th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $0.85 per share for the quarter, up from their prior forecast of ($1.69). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($5.60) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($1.72) EPS, FY2024 earnings at ($5.53) EPS, Q1 2025 earnings at ($1.56) EPS, Q2 2025 earnings at ($1.37) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($4.81) EPS and FY2026 earnings at $1.37 EPS.

ASND has been the subject of a number of other research reports. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday. Morgan Stanley raised their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a report on Thursday, May 16th. Finally, Evercore ISI raised shares of Ascendis Pharma A/S to a “strong-buy” rating in a report on Monday, August 26th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $187.08.

Ascendis Pharma A/S Stock Down 0.4 %

Shares of Ascendis Pharma A/S stock opened at $119.00 on Friday. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The company has a 50 day moving average of $134.73 and a 200 day moving average of $138.46. The company has a market capitalization of $6.93 billion, a P/E ratio of -12.38 and a beta of 0.63.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Westfield Capital Management Co. LP grew its position in Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after buying an additional 44,580 shares during the last quarter. Capital International Investors grew its position in Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after buying an additional 93,185 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.